Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acetoacetyl-CoA synthetase (AACS) is a cytosolic enzyme that catalyzes the ligation of acetoacetate with CoA using ATP, resulting in the production of acetoacetyl-CoA, AMP, and pyrophosphate[2]. It is a key enzyme in the anabolic utilization of ketone bodies, allowing tissues to synthesize cholesterol and fatty acids directly from ketone bodies, bypassing the citrate/ATP citrate lyase pathway. This pathway is particularly important in actively lipogenic tissues such as liver, adipose tissue, mammary gland, skin, intestinal mucosa, adrenals, and brain[2]. AACS is a member of the acyl-CoA synthetase family and is regulated in a tissue-specific manner according to lipid synthesis needs. Its structure and catalytic mechanism involve significant domain motions typical of adenylate-forming enzymes (ANL superfamily). Deficiencies or mutations in related enzymes can cause inherited metabolic disorders, especially those involving ketone body metabolism[3].
Ligase catalysis (conversion of acetoacetate, CoA, and ATP to acetoacetyl-CoA, AMP, and pyrophosphate)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acetoacetyl-CoA synthetase (AACS).